Get the Daily Brief
Latest Biotech News
Abivax Ulcerative Colitis Drug Surges on Positive Phase 3 Data
French biotech Abivax saw its stock surge over 500% after reporting positive Phase 3 trial results for obefazimod, an oral miRNA-124 enhancer for moderate to severe ulcerative colitis. The pooled...
Dispatch Bio Launches with $216M to Develop Universal Solid Tumor Therapy
Dispatch Bio, backed by $216 million in funding from Arch Venture Partners, Parker Institute, and industry leaders, launched with a platform targeting a universal solid tumor treatment. Its Flare...
Thermo Fisher Raises 2025 Outlook After Strong Q2 Performance
Thermo Fisher Scientific posted a 3% year-over-year revenue increase in Q2 2025 to $10.86 billion, surpassing analyst expectations. Key segments like life sciences solutions and laboratory...
AstraZeneca Advances Treatments with Positive Trial Data and U.S. Investment
AstraZeneca reported positive Phase 3 results for gefurulimab in myasthenia gravis, achieving all primary and secondary endpoints and demonstrating meaningful clinical improvement. The company...
FDA Launches Priority Fast Track to Accelerate National Health Projects
The FDA introduced the Commissioner’s National Priority Voucher (CNPV) pilot program, offering accelerated one- to two-month reviews for projects aligned with U.S. health priorities such as...
TCG Labs Soleil Secures $400 Million to Expand Biotech Startup Portfolio in China
TCG Labs Soleil, a venture capital and biotech R&D operator, announced a $400 million funding round to accelerate the launch and development of its portfolio of single-asset biotechnology...
FDA Delays GSK’s Blenrep Decision After Advisory Committee’s Negative Vote
The FDA postponed its decision to October 23 on GSK’s Blenrep for multiple myeloma following a negative recommendation from the Oncologic Drugs Advisory Committee. The delay allows additional...
Abivax’s Ulcerative Colitis Drug Surges on Phase 3 Trial Success
French biotech Abivax's shares soared amid positive Phase 3 results for its experimental miRNA-124 enhancer, obefazimod, in treating moderately to severely active ulcerative colitis. Two pivotal...
Dispatch Bio Unveils $216 Million Solid Tumor Immunotherapy Backed by Carl June
Dispatch Bio, a new biotechnology company launched in 2022, revealed a $216 million fundraising milestone alongside its innovative two-component immunotherapy for solid tumors. The platform...
Roche Faces Hurdles as It Halts Elevidys Gene Therapy Shipments Outside US
Roche has temporarily suspended new orders of Duchenne muscular dystrophy gene therapy Elevidys in several countries that depend on FDA approval, responding to safety concerns including liver...
Arrowhead Pharmaceuticals Confirms Sarepta Deal Amid Partner’s Turmoil
Arrowhead Pharmaceuticals reassured investors it expects Sarepta Therapeutics to uphold its financial commitments under their multi-hundred-million-dollar deal involving RNA therapy programs....
FDA Launches National Priority Voucher Pilot with 2-Month Review for Onshoring, Affordability
The FDA introduced the Commissioner’s National Priority Voucher (CNPV) pilot program aimed at expediting review times to one or two months for drugs aligning with critical U.S. health priorities....
New Human Genome Studies Resolve Structural Variants and Complex Regions
Two major studies published in Nature detailed enhanced genomic resolution from sequencing 65 diverse human genomes, including full telomere-to-telomere assemblies and comprehensive structural...
Boehringer Ingelheim Awaits FDA Decisions on Lung Cancer and IPF Drugs
Boehringer Ingelheim is poised for major milestones pending FDA regulatory decisions on two late-stage candidates: zongertinib, a HER2-selective tyrosine kinase inhibitor targeting advanced...
Dispatch Bio Launches With $216M to Target Solid Tumors
Dispatch Bio debuted with $216 million in funding, aiming to develop a universal immunotherapy for solid tumors. The biotech, founded in 2022 by CAR-T pioneer Carl June and colleagues, uses a...
Abivax Ulcerative Colitis Drug Posts Strong Phase 3 Data, Shares Surge
Abivax's oral miRNA-124 enhancer, obefazimod, demonstrated significant efficacy in two phase 3 trials for moderately to severely active ulcerative colitis, achieving a 16.4% placebo-adjusted...
Roche Diagnostics Revenues Decline Amid China Pricing Pressures
Roche reported a 3% year-over-year decline in its Diagnostics division revenues for the first half of 2025, attributed in part to healthcare pricing reforms in China. Overall sales rose 4% to CHF...
FDA Extends Review for GSK Multiple Myeloma Drug Blenrep
The U.S. Food and Drug Administration has extended the review period for GSK’s blood cancer drug Blenrep by three months, delaying its potential relaunch in the U.S. The continuation follows a...
Roche Pauses Shipments of Sarepta’s Duchenne Gene Therapy Abroad
Roche has temporarily halted shipments of Elevidys, a Duchenne muscular dystrophy gene therapy marketed outside the United States, amid mounting safety concerns including liver injuries linked to...
Thermo Fisher Beats Q2 Estimates, Raises 2025 Guidance on Cost Cuts
Thermo Fisher Scientific reported better-than-expected Q2 2025 results, with revenues up 3% year-over-year to $10.86 billion and adjusted EPS of $5.36 surpassing consensus. Growth was notable in...